Supplementary Table 2 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table 2. Average B7-H3 Expression Patterns for Treated Patients by Diagnosis
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4414101715